The costs and benefits of an early access scheme for oncology medicines in Ireland
Kevin Morris, Mark Pennington, Colette Whitelegg, Luke Parkes, Ronan Mahon · 2026
Read The costs and benefits of an early access scheme for oncology medicines in Ireland by Kevin Morris, Mark Pennington, Colette Whitelegg, Luke Parkes, Ronan Mahon (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13455194.txt.
Description
Kevin Morris and others examined the costs and gains of an early access plan for cancer medicines in Ireland in 2026, modeling a cost-sharing agreement to speed access. New oncology medicines face delays from lengthy appraisal, and early access schemes could cut waiting time if manufacturers share initial costs. The team modeled medicines commencing appraisal in 2022.
Under the scheme, manufacturers would pay costs for the first 180 days and give a further rebate if per-patient costs over full access exceeded those from the finally agreed price. Costs and savings from displaced therapies were estimated daily from National Centre for Pharmacoeconomics technical summaries. The scheme would have cut average waiting time by more than two years. Assuming thirty percent discounts at reimbursement, the analysis quantifies trade-offs for policymakers.
Catalog record
| CREATOR | Kevin Morris, Mark Pennington, Colette Whitelegg, Luke Parkes, Ronan Mahon |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |